Viewing StudyNCT00394251



Ignite Creation Date: 2024-05-05 @ 5:10 PM
Last Modification Date: 2024-10-26 @ 9:28 AM
Study NCT ID: NCT00394251
Status: COMPLETED
Last Update Posted: 2019-11-25
First Post: 2006-10-30

Brief Title: Study of Dose-dense Adriamycin Plus Cytoxan AC Followed by Either ABI-007 Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Sponsor: Celgene
Organization: Celgene

Conditions & Keywords Data

Conditions:
Name
Breast Cancer
Keywords:
Name View
Early stage breast cancer View
Adjuvant therapy View
Bevacizumab View
Abraxane View